Swine Interferon-Inducible Transmembrane Proteins Potently Inhibit African Swine Fever Virus Replication

Siqi Cai1,2,3†, Zezhong Zheng1,2,4†, JiaoJiao Cheng1,2,3, Lintao Zhong1,2,5, Ran Shao1,2,4, Feiyan Zheng1,2,4, Zhiying Lai1,2,5, Jiajun Ou1,2,4, Liang Xu1,2,4, Pei Zhou1,2,4*, Gang Lu1,2,5* and Guihong Zhang1,2,3*

1 Guangdong Provincial Key Laboratory of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China, 2 African Swine Fever Regional Laboratory of China (Guangzhou), Guangzhou, China, 3 Maoming Branch, Guangdong Laboratory for Lingnan Modern Agriculture, Maoming, China, 4 Key Laboratory of Animal Vaccine Development, Ministry of Agriculture and Rural Affairs, Guangzhou, China, 5 Research Center for African Swine Fever Prevention and Control, South China Agricultural University, Guangzhou, China

African swine fever virus (ASFV) causes an acute, hemorrhagic, and highly contagious disease in domestic swine, leading to significant economic losses to the global porcine industry. Restriction factors of innate immunity play a critical role in host antiviral action. However, function of swine restriction factors of innate immunity on ASFV has been seldomly investigated. In this study, we determined five homologues of swine interferon-induced transmembrane proteins (SwIFITM [named SwIFITM1a, -1b, -2, -3, and -5]), and we found that they all exhibit potent antiviral activity against ASFV. Expression profile analysis indicated that these SwIFITMs are constitutively expressed in most porcine tissues. Whether infected with ASFV or treated with swine interferon, the expression levels of SwIFITMs were induced in vitro. The subcellular localization of SwIFITMs was similar to that of their human homologues. SwIFITM1a and -1b localized to the plasma membrane, SwIFITM2 and -3 focused on the cytoplasm and the perinuclear region, while SwIFITM5 accumulated in the cell surface and cytoplasm. The overexpression of SwIFITM1a, -1b, -2, -3, or -5 could significantly inhibit ASFV replication in Vero cells, whereas knockdown of these genes could enhance ASFV replication in PAMs. We blocked the constitutive expression of endogenous IFITMs in Vero cells using a CRISPR-Cas9 system and then infected them with ASFV. The results indicated that the knockout of endogenous IFITMs could enhance ASFV replication. Finally, we expressed five SwIFITMs in knockout...
African swine fever virus (ASFV) (9). Human IFITMs have been identified ssaviruses to a similar level as its human orthologue (8), and Rana grylio virus (7), IFITM3 protein restricts cell infection by DNA viruses. One recent study found that IFITM1 could inhibit little is known about the IFITM-mediated antiviral impact on fusion (10). Additionally, some IFITMs can block viral entry by suppressing viral membrane Nila virus, hepatitis C virus, and dengue virus (1–6). However, little is known about the IFITM-mediated antiviral impact on DNA viruses. One recent study found that IFITM1 could inhibit Rana grylio virus (7), IFITM3 protein restricts cell infection by lyssaviruses to a similar level as its human orthologue (8), and human IFITMs have been identified as restriction factors for African swine fever virus (ASFV) (9).

IFITM proteins can impede broad-spectrum viral infection through various mechanisms. It is generally believed that IFITMs can block viral entry by suppressing viral membrane fusion (10). Additionally, some findings have indicated that IFITMs might also inhibit viral gene expression and viral protein synthesis and thereby impair viral replication. IFITMs may incorporate into virions during viral assembly and thus reduce the infectivity of nascent virions. The precise inhibitory mechanisms of IFITMs on viral infection and replication still require further exploration (11, 12).

To date, five swine IFITMs (SwIFITMs) have been found. These are located on chromosome 2, and they are referred to as SwIFITM1, -2, -3, -5, and -10. For SwIFITM1, there are two homologues differing in their N- and C-terminals, and these are named SwIFITM1a and -1b (13). Although IFITM5 is expressed mainly in osteoblasts and is required for bone mineralization (14), one study found that murine IFITM5 does not restrict IAV, but it efficiently inhibits filovirus infection (15). Few studies on IFITM10 have been reported, and its function remains largely unknown (14). IFITMs are widely distributed in cells, but there are great differences in the distribution and expression of their different subtypes (16). The differences in the subcellular localization and organelle distribution of SwIFITMs leads to the selectivity of their inhibitory effects on different viruses; that is, the sensitivity of a particular virus to different members of the family is different (17).

ASFV is the only member of the Asfarviridae family, and it causes an acute, hemorrhagic, and highly contagious disease affecting domestic swine. This often results in serious economic losses in many countries, especially China, due to the mortality rate of acute infection being close to 100% (18, 19). Currently, no commercial antiviral drugs are available for its control and effective treatment. SwIFITMs are a group of antiviral restriction factors that may target cell entry, gene duplication and transcription, protein translation, and virus assembly in the virus-replication cycle, which means that it may be possible to develop them as antiviral drugs or vaccine targets. In this study, we examined whether the SwIFITM family of proteins can affect ASFV infection.

**INTRODUCTION**

Interferons (IFNs) play an essential role in host defense against viral infections by inducing the expression of a variety of IFN-stimulated genes (ISGs) that can activate host antiviral immunity. interferon-induced transmembrane proteins (IFITMs) are a family of small transmembrane proteins that are critical ISG products. Compelling evidence has indicated that IFITMs can establish an innate immune state to eliminate pathogens efficiently (1, 2). IFITMs are known to inhibit the entry of a wide variety of RNA viruses, especially enveloped viruses such as the Ebola virus, influenza A virus (IAV), West Nile virus, hepatitis C virus, and dengue virus (1–6). However, little is known about the IFITM-mediated antiviral impact on DNA viruses. One recent study found that IFITM1 could inhibit Rana grylio virus (7), IFITM3 protein restricts cell infection by lyssaviruses to a similar level as its human orthologue (8), and human IFITMs have been identified as restriction factors for African swine fever virus (ASFV) (9).

IFITM proteins can impede broad-spectrum viral infection through various mechanisms. It is generally believed that IFITMs can block viral entry by suppressing viral membrane fusion (10). Additionally, some findings have indicated that IFITMs might also inhibit viral gene expression and viral protein synthesis and thereby impair viral replication. IFITMs may incorporate into virions during viral assembly and thus reduce the infectivity of nascent virions. The precise inhibitory mechanisms of IFITMs on viral infection and replication still require further exploration (11, 12).

To date, five swine IFITMs (SwIFITMs) have been found. These are located on chromosome 2, and they are referred to as SwIFITM1, -2, -3, -5, and -10. For SwIFITM1, there are two homologues differing in their N- and C-terminals, and these are named SwIFITM1a and -1b (13). Although IFITM5 is expressed mainly in osteoblasts and is required for bone mineralization (14), one study found that murine IFITM5 does not restrict IAV, but it efficiently inhibits filovirus infection (15). Few studies on IFITM10 have been reported, and its function remains largely unknown (14). IFITMs are widely distributed in cells, but there are great differences in the distribution and expression of their different subtypes (16). The differences in the subcellular localization and organelle distribution of SwIFITMs leads to the selectivity of their inhibitory effects on different viruses; that is, the sensitivity of a particular virus to different members of the family is different (17).

ASFV is the only member of the Asfarviridae family, and it causes an acute, hemorrhagic, and highly contagious disease affecting domestic swine. This often results in serious economic losses in many countries, especially China, due to the mortality rate of acute infection being close to 100% (18, 19). Currently, no commercial antiviral drugs are available for its control and effective treatment. SwIFITMs are a group of antiviral restriction factors that may target cell entry, gene duplication and transcription, protein translation, and virus assembly in the virus-replication cycle, which means that it may be possible to develop them as antiviral drugs or vaccine targets. In this study, we examined whether the SwIFITM family of proteins can affect ASFV infection.

**MATERIALS AND METHODS**

**Cells and Viruses**

Human embryonic kidney cells (HEK-293T), Porcine Kidney-15 cells (PK-15), and Vero cells (ATCC CCL-81) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; BI). Porcine alveolar macrophages (PAMs) were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FBS. The GZ201801 strain of ASFV (GenBank: MT496893.1) was obtained from the Research Center for African Swine Fever Prevention and Control, South China Agricultural University (Guangzhou, China), which was a highly pathogenic strain belonging to p72 genotype II. Experiments involving ASFV were standardized according to the Laboratory Biosafety Manual and strictly performed in the P3 biosafety laboratory.

**Real-Time Quantitative PCR (RT-qPCR)**

Specific primers and probes were designed based on the genetic sequences of swine IFITM1a, -1b, -2, -3, -5, β-actin, and Mx1, as well as ASFV p72 (Table 1). RT-qPCR was performed to define the relative mRNA expression of IFITMs and ASFV using a LightCycler 480 (Roche, Basel, Switzerland). Cells were treated with RNAiso Plus (Takara, Dalian, China) to extract total RNA, which was reversed transcribed into cDNA using the HiScript Q RT SuperMix for qPCR (Vazyme, Nanjing, China). RT-qPCR was performed using the TB Green Premix Ex Taq II kit (Takara, Dalian, China) or the AceQ qPCR Master Mix kit (Vazyme, Nanjing, China) according to the manufacturer’s instructions. Relative fold changes in gene expression were normalized against β-actin using the 2^ΔΔCt threshold method.

**Construction and Transfection of Plasmids and siRNAs**

FLAG-tagged swine IFITM1a, -1b, -2, -3, and -5 were inserted into the eukaryotic expression vector pEF6/Myc-His (Life Technologies) to generate pEF-SwIFITMs. Small interfering RNAs (siRNAs)
named siIFITM1a,1b,2 targeting SwIFITM1a, -1b and -2, two different siRNAs named siIFITM3 and siIFITM5 targeting SwIFITM3 and -5, respectively, and a negative-control nontargeting siRNA (siNC) were designed with the siRNA Designer website (Ribobio, Guangzhou, China). The plasmids and siRNAs were respectively transfected into Vero cells and PAMs using Lipo3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

### Establishment of Knockout Cell Lines

To make lentivirus, the lentiviral transfer plasmid lentiCRISPRv2-DsRed2 containing expression cassettes of hSpCas9 and the chimeric guide RNA modified from lentiCRISPRv2 (Addgene 52961) must be co-transfected into HEK293T cells with the packaging plasmid pMD2.G (Addgene 12259) and VSV-G envelope expressing plasmid psPAX2 (Addgene 12260) (20). Three different small guide RNAs

#### Table 1

| Gene | Primer sequence (5′–3′) | Purpose |
|------|--------------------------|---------|
| **SwIFITM1a** | F: ATGATCAAGAGCCAGCACG | Amplification of SwIFITM1a |
| | R: CTAGTACGCTGTGTTACCTTTCG | |
| **SwIFITM1b** | F: ATGCTGAGGAGGAGCAC | Amplification of SwIFITM1b |
| | R: CTAGTACGCTGTGTTACCTTTCG | |
| **SwIFITM2** | F: ATGACTGCGGCTCCCGC | Amplification of SwIFITM2 |
| | R: CTAGTACGCTGTGTTACCTTTCG | |
| **SwIFITM3** | F: ATGACCTGCTGCGCGCAG | Amplification of SwIFITM3 |
| | R: CTACGTCTAGTGGTACCTTGAA | |
| **SwIFITM5** | F: ATAGGCGCACGAGCGCACG | Amplification of SwIFITM5 |
| | R: TTCTCTGAGGAGCGACG | |
| **Sw-β-actin** | F: TCTGTAAGAGGAAGAGCATCACT | RT-qPCR detection of swine β-actin |
| | R: TTCTCTGAGGAGCGACG | |
| **Sw-Mx1** | F: GGGACCTGCTGCTGCTG | RT-qPCR detection of SwIFITM1a |
| | R: TTCTCTGAGGAGCGACG | |
| **SwIFITM1a** | F: GGGACCTGCTGCTGCTG | RT-qPCR detection of SwIFITM1a |
| | R: TTCTCTGAGGAGCGACG | |
| **SwIFITM2** | F: GGGACCTGCTGCTGCTG | RT-qPCR detection of SwIFITM2 |
| | R: TTCTCTGAGGAGCGACG | |
| **SwIFITM3** | F: GGGACCTGCTGCTGCTG | RT-qPCR detection of SwIFITM3 |
| | R: TTCTCTGAGGAGCGACG | |
| **SwIFITM5** | F: GGGACCTGCTGCTGCTG | RT-qPCR detection of SwIFITM5 |
| | R: TTCTCTGAGGAGCGACG | |
| **ASFV p72** | F: ATAGGCGCACGAGCGCACG | RT-qPCR detection of ASFV |
| | R: TTCTCTGAGGAGCGACG | |
| **siRNA1a,1b,2** | CTGTTCTTCTGTGTTT | siRNA targeting SwIFITM1a, -1b and -2 |
| **siRNA3** | GCGTGTACATCGCTGTTGCA | siRNA targeting SwIFITM3 |
| **siRNA5** | GCGTGTACATCGCTGTTGCA | siRNA targeting SwIFITM5 |
| **Flag-tagged** | F: ATAGGCGCACGAGCGCACG | Amplification of FLAG-tagged |
| **SwIFITM1a** | F: GGGGTACCGCCACCATGGAATTACACAGGATGACGACGATACCCAGCAAGAGCCAGCACG | Amplification of FLAG-tagged |
| | R: CCGGAATTCCTAGTAGCCTCTGTTACCTTTCG | SwIFITM1a |
| **Flag-tagged** | F: ATAGGCGCACGAGCGCACG | Amplification of FLAG-tagged |
| **SwIFITM1b** | F: GGGGTACCGCCACCATGGAATTACACAGGATGACGACGATACCCAGCAAGAGCCAGCACG | Amplification of FLAG-tagged |
| | R: CCGGAATTCCTAGTAGCCTCTGTTACCTTTCG | SwIFITM1b |
| **Flag-tagged** | F: ATAGGCGCACGAGCGCACG | Amplification of FLAG-tagged |
| **SwIFITM2** | F: GGGGTACCGCCACCATGGAATTACACAGGATGACGACGATACCCAGCAAGAGCCAGCACG | Amplification of FLAG-tagged |
| | R: CCGGAATTCCTAGTAGCCTCTGTTACCTTTCG | SwIFITM2 |
| **Flag-tagged** | F: ATAGGCGCACGAGCGCACG | Amplification of FLAG-tagged |
| **SwIFITM3** | F: GGGGTACCGCCACCATGGAATTACACAGGATGACGACGATACCCAGCAAGAGCCAGCACG | Amplification of FLAG-tagged |
| | R: CCGGAATTCCTAGTAGCCTCTGTTACCTTTCG | SwIFITM3 |
| **Flag-tagged** | F: ATAGGCGCACGAGCGCACG | Amplification of FLAG-tagged |
| **SwIFITM5** | F: GGGGTACCGCCACCATGGAATTACACAGGATGACGACGATACCCAGCAAGAGCCAGCACG | Amplification of FLAG-tagged |
| | R: CCGGAATTCCTAGTAGCCTCTGTTACCTTTCG | SwIFITM5 |
| **sgRNA-1** | GATGTTTTGCGATGATCG | sgRNA targeting exon 1 of csIFITM1 |
| | GATGTTTTGCGATGATCG | |
| **sgRNA-3** | GTGTGATGATGATGATCG | sgRNA targeting exon 1 of csIFITM3 |
| | GTGTGATGATGATGATCG | |
| **sgRNA-5** | GGCGCGCGCGCGCGCGCG | sgRNA targeting exon 1 of csIFITM5 |
| | GGCGCGCGCGCGCGCGCG | |
| **csIFITM1** | F: ATAGGCGCACGAGCGCACG | Detection of knock out of csIFITM1 |
| | R: ATGACACTGCTGCTGCTG | |
| **csIFITM3** | F: ATAGGCGCACGAGCGCACG | Detection of knock out of csIFITM3 |
| | R: ATGACACTGCTGCTGCTG | |
| **csIFITM5** | F: ATAGGCGCACGAGCGCACG | Detection of knock out of csIFITM5 |
| | R: ATGACACTGCTGCTGCTG | |

F, Forward; R, Reverse; P, Probe.

---

Cai et al. Swine IFITMs Inhibit ASFV Replication

Frontiers in Immunology | www.frontiersin.org March 2022 | Volume 13 | Article 827709
(sgRNAs) targeting the *Chlorobius sabacua* IFITMs (csIFITMs) designed with the sgRNA Designer website (https://zlab.bioguide-design-resource) were inserted into the lentiviral vector lentCRISPRV2-DsRed2 to generate lentCRISPRV2-DsRed2-csIFITMs. The lentiviruses were created by 0.5 µg pMD2.G, 0.5 µg psPAX2, 1 µg empty lentCRISPRV2-DsRed2, or lentCRISPRV2-DsRed2-csIFITMs, which were co-transfected into HEK-293T cells using Lipo3000 transfection reagent with Opti-MEM (Life Technologies) in six-well plates. Lentiviruses were dispersed into PAMs and titrated in triplicate using 10-fold serial dilutions. Cultures were observed for Hemadsorption (HAD) phenomena on day 7 post-infection. The HAD_{50/mL} values were calculated by using the Reed and Muench method (22).

**Confocal Immunofluorescence Microscopy**

The PK-15 cells were transfected with swine IFITM expression constructs in glass-bottomed coverslips (NEST Biotechnology, Wuxi, China) for 24 h. Then, the cells were fixed with 4% (vol/vol) paraformaldehyde at 4°C for 30 min. Following cell fixation, QuickBlock Blocking Buffer for Immununol Staining (Beyotime, Shanghai, China) was used. All the samples were stained with ANTI-FLAG monoclonal antibody (Sigma-Aldrich) to detect IFITM proteins and anti-LAMP1 monoclonal antibody (Abcam; ab150113) and Alexa Fluor 594 conjugated goat anti-mouse polyclonal antibody (Abcam; ab186695) and Alexa Fluor 680 conjugated goat anti-rabbit polyclonal antibody (Abcam; ab186696). Protein bands were visualized by Odyssey Sa (LI-COR, Lincoln, NE, USA). WB quantification by densitometry for each viral proteins or SwIFITM proteins and beta-actin are expressed using the ImageJ package.

**HAD Assay**

The ASFV was quantified using the hemadsorption (HAD) assay as previously described (21). PAMs were seeded in 96-well plates with 1% pig blood cells. Viral samples were then inoculated into PAMs and titrated in triplicate using 10-fold serial dilutions. Cultures were observed for Hemadsorption (HAD) phenomena on day 7 post-infection. The HAD_{50/mL} values were calculated by using the Reed and Muench method (22).

**Cell Proliferation Assay**

The CCK-8 Cell Counting Kit (Vazyme, Nanjing, China) was used to determine the proliferation of WT, control or csIFITMs Vero cells. Briefly, the three Vero cells were distributed into 96-well plates, and their proliferation was then detected every 12 h. Besides, the WT and csIFITMs Vero cells were transiently transfected with five pEF-SwIFITMs or empty plasmid pEF6/Myc- His for 24 h and then infected with ASFV for 36 h; their proliferation was detected every 6 hours after transfection. The experiments were included with three replicates and non-transfected blank and empty plasmid control was included. CCK8 was added and incubated for 1 h; the absorbance was measured at 450 nm.

**Statistical Analysis**

GraphPad Prism v6.02 was used for all statistical significance calculations using the conventional Student’s *t*-test. Values are presented as the mean ± SD of three independent experiments. *P*-values of <0.05 were considered to indicate statistical significance (*p*<0.05; **p*<0.01; ***p*<0.001; ****p*<0.0001).

**RESULTS**

**Expression Levels of SwIFITMs**

To understand expression levels of SwIFITMs in different porcine tissues, we collected 13 tissue samples (heart, liver, spleen, lung, kidney, tonsil, trachea, thymus, superior cervical lymph node, muscle, superficial inguinal lymph node, small intestine, and mesenteric lymph node), and we then quantified their IFITM expression levels by RT-qPCR (Figure 1A). In this study, SwIFITMs were constitutively expressed in most porcine tissues, and the expression levels of SwIFITM1, 2, and 3 were the highest in the liver or lung and the lowest in the small intestine. SwIFITM5 was expressed at a low level in each tissue. Moreover, the expression levels of other IFITMs were not constant between different tissues. RT-qPCR results showed that most SwIFITMs had an expression level of >10^{-5}-fold that of β-actin, except thymus SwIFITM1b and all of SwIFITM5.
In PAMs (Figure 1B), SwIFITM1a, -2, and -3 had an expression level of $10^{-3}$–$10^{-2}$ fold that of β-actin. The expression levels of SwIFITM1a and -2 were equal to that of SwIFITM3, and the expression levels of SwIFITM1b and -5 were significantly lower than that of SwIFITM3 ($p<0.01$). Then, we estimated the expression level of SwIFITMs in vitro when PAMs were treated with recombinant porcine interferon-α (Novus, IFN-α) (1000 U, 10 000 U) (Figure 1C). As a control, addition of IFN-α caused an increase in the expression of swine Mx1 in PAMs. The expression of all SwIFITMs was up-regulated ($p<0.001$). Interestingly, it was observed that IFN-α induced the highest up-regulation of about 256-fold the SwIFITM3 expression. Next, we investigated the expression of SwIFITMs in vitro when PAMs were infected with ASFV (GZ201801, 0.01, 0.1 MOI) (Figure 1D). At 24 hpi, ASFV caused an increase in the expression of all SwIFITMs ($p<0.01$). To assess when the expression of SwIFITMs triggered in PAMs during infection of ASFV (0.1 MOI), we determined the expression of SwIFITMs each 6 h from 0 to 36 hpi (Figure 1E). The expression of all SwIFITMs was ascended as early as 6 hpi and reached the peak at 12 hpi which indicated that the expression of SwIFITMs was up-regulated before ASFV had achieved replication.

Subcellular Localization of SwIFITM Proteins
To determine the subcellular localization of SwIFITMs, PK-15 cells and Vero cells were transiently transfected with five pEF-SwIFITMs including an N-terminal FLAG tag for 24 h, and they were then evaluated by confocal immunofluorescence microscopy (Figures 2A, B). In PK-15 cells, it was revealed that SwIFITM1a and -1b localized predominantly to the plasma membrane, but SwIFITM3 mainly focused on the cytoplasm and the perinuclear region, otherwise SwIFITM2 and -5 accumulated in the plasma membrane and the cytoplasm. Confocal microscopy revealed that only SwIFITM3 and -5 were colocalized with LAMP1 in late endosomal compartments in PK-15 cells. In Vero cells, it was observed that SwIFITM1a and -1b localized predominantly to cell surface similar to PK-15 cells, whereas SwIFITM2 and -3 was present the cytoplasm and the perinuclear region, and SwIFITM5 localized in the cell surface and the cytoplasm. SwIFITM3 and -5 had colocalization with LAMP1, but the amount of colocality of SwIFITM5 and LAMP1 in Vero cells was significantly lower than that in PK-15 cells. SwIFITMs localized to distinct cellular compartments.

Knockdown of SwIFITMs Enhances ASFV Replication
To primarily explore the effect of SwIFITMs on ASFV replication, we designed and synthesized three different siRNAs to knockdown endogenous SwIFITMs. Because of the high nucleotide-sequence homologies of SwIFITM1a, -1b and -2, we designed a single siRNA targeting all three of them. The siRNAs were transfected into PAMs separately for 24 h (Figures 3A–C) and then infected with ASFV. At 36 hpi, all samples were harvested to detect their virus replication
levels by RT-qPCR and WB (Figures 3D–F) using an ASFV p72 probe, anti-ASFV p30 polyclonal antibody and anti-ASFV p72 polyclonal antibody, besides, the viral titration of progeny virus was tested in HAD assay (Figure 3G). The results indicated that the parameters relating to ASFV replication in siIFITM1a,1b,2, siIFITM3 and siIFITM5 were significantly increased compared with the siNC group. Although siIFITM1a,1b,2 caused the highest replication levels of ASFV, further study is needed to verify the relationship between these three genes and ASFV restriction because, as noted, siRNA1a,1b,2 jointly targeted SwIFITM1a, -1b, and -2.

**Overexpression of SwIFITMs Inhibits ASFV Replication**

Next, we analyzed the impact of SwIFITM overexpression on ASFV replication. Vero cells were transiently transfected with five pEF-SwIFITMs for 24 h and then infected with ASFV. At 36 hpi, all samples were collected to detect the cells proliferation assay and their virus replication levels by RT-qPCR, WB and HAD assay (Figures 4A–E). The results of the cells proliferation assays indicated that the cells viability in transfected cells with the different SwIFITM were not significantly different from that of the empty plasmid control or non-transfected cells. Compared with control infection, the viral production of ASFV in the five overexpression experimental groups was significantly decreased, indicating that SwIFITM1a, -1b, -2, -3, and -5 can restrict ASFV replication. The HAD assay results further verified that all the SwIFITMs overexpression reduced ASFV replication.

**Generation and Validation of csIFITM Knockout Vero Cell Lines**

Because Vero cells constitutively express endogenous IFITMs that could interfere with subsequent experiments, it is necessary to construct knockout Vero cell lines that block endogenous IFITMs. Three different sgRNAs targeting the csIFITM1, -3, and -5 first exons were designed and inserted into the lentiviral vector lentCRISPRv2-DsRed2 to generate lentCRISPRv2-DsRed2-csIFITMs. These were used to establish the knockout cell lines by a lentiviral transduction system and were screened by limiting dilution assay. Once the csIFITM- Vero cells were established, the knockout of csIFITMs was determined by Sanger sequencing validation or WB analysis (Figures 5A, B). The Sanger sequencing results showed that csIFITM1, -3, and -5 respectively had 4, 7, and 5 bp deletion mutations in the csIFITMs− Vero cells. The WB results further verified that the csIFITM genes in the Vero cells were successfully knocked out, and the csIFITMs− Vero cell line was obtained.

Interestingly, due to the failure to successfully find and amplify csIFITM2, we did not attempt to knock out IFITM2 at the same time, but the WB results showed that csIFITM2 was nonetheless knocked out. This indicates that csIFITM2 may be highly homologous with csIFITM3, resulting in its simultaneous knockout. Next, we detected the proliferation of the csIFITMs−, control, and WT Vero cells using the CCK-8 Cell Counting Kit (Figure 5C). The results showed that the proliferation of the csIFITMs− Vero cells was not significantly different from that of the control and WT Vero cells, suggesting that the knockout of csIFITMs did not affect cell viability. Finally, the three types of cells were infected with ASFV. All samples were collected to detect their virus replication levels by RT-qPCR, WB and HAD assay at 36 hpi (Figures 5D–G). The results indicated that the viral production of ASFV in csIFITMs− Vero cells was significantly increased: more than 10-fold when compared with the control and WT Vero cells.

**Antiviral Effect of SwIFITMs on ASFV**

To analyze the antiviral effect of SwIFITMs on ASFV infection in csIFITMs− Vero cells, csIFITMs− Vero cells were transiently

---

**FIGURE 2** | Subcellular localization of SwIFITMs in PK-15 cells and Vero cells. The cell nucleus, expression of SwIFITM1a, -1b, -2, -3, and -5 proteins, and LAMP1-positive late endosomes (red) in (A) PK-15 cells and (B) Vero cells are indicated by blue, green, and red, respectively.
transfected with five pEF-SwIFITMs for 24 h, and they were then infected with ASFV. At 36 hpi, all samples were collected to detect the cells proliferation assays and their virus replication levels by RT-qPCR, WB and HAD assay (Figures 6A–E). The results of the cells proliferation assay indicated that there was no significant difference in cell viability under all conditions. Compared with control infection, the overexpression of SwIFITM1a, -1b, -2, -3, or -5 restricted the replication of ASFV. The HAD assay results were further confirmed that each of the SwIFITMs overexpression restricted ASFV replication.

**DISCUSSION**

After infection with pathogens such as bacteria or viruses, host cells activate innate immune responses as their first line of defense. As downstream effector molecules in the natural immune system, natural immune factors are an important part of the antiviral natural immune system (23, 24). They have a wide variety—there are more than 1000—and they have a variety of strategies to limit virus replication. The cytokine group known as IFN encodes a variety of natural antiviral immune effectors through the induction cascade of ISG. Among these, IFITM is an important protein in the CD225 protein superfamily that is intensely induced during viral infection, and it is widely distributed in animal cells (25). SwIFITMs have been shown to widely inhibit viral infection, especially in RNA viruses like porcine reproductive and respiratory syndrome virus, classical swine fever virus, and IAV (26–28).

As the only known DNA arbovirus, ASFV has strong environmental resistance and a wide range of transmission routes. As such, it causes significant economic losses to the global porcine industry (19, 29). However, there have as yet been no reports of studies on the antiviral effects of SwIFITMs on ASFV. In this work, we verified the SwIFITM expression patterns
in different porcine tissues and PAMs, as well as the subcellular localization in PK-15 cells, and we identified its antiviral activity against ASFV in PAMs and Vero cells.

Because most vertebrate IFITM families contain multiple IFITM homologues (25, 30), we successfully amplified SwIFITM1a, -1b, -2, -3, and -5 which contained the same key amino acid sites and functional domains (13). We then analyzed the expression levels of SwIFITMs, and the results indicated that SwIFITMs are constitutively expressed in most porcine tissues. We also found that IFN treatment or virus infection could induce SwIFITM expression in PAMs.

The subcellular localization of SwIFITM proteins in PK-15 cells and Vero cells, and its localization patterns associated with endocytic compartments, especially late endosomal region, was partly coincident with previous reports. The results revealed that SwIFITM1a and -1b localized predominantly to the plasma membrane, but SwIFITM3 mainly focused on the cytoplasm and the perinuclear region, which is mostly similar to the distribution of their human homologues. We also identified that SwIFITM2 and -5 accumulated in the cell surface and cytoplasm. In a previous study, swine and human SwIFITM2 and -3 were found to share an N-terminal extension of about 20 amino acids that contains the endocytosis motif YEML, and all the SwIFITM1a, -1b and -5 lack the same motif structure (31, 32). Interestingly, we also found that the overexpression of SwIFITM5 was colocalized with the late endosomal marker LAMP1, which might be attributed to the alteration of the lysosome distribution by overexpression or the interaction with IFITM5 proteins and other IFITM paralogues (33, 34).

We have now determined that all five SwIFITMs have an antiviral effect on ASFV replication. The overexpression of SwIFITM1a, -1b, -2, -3, or -5 could significantly inhibit ASFV replication in Vero cells, whereas knockdown of these genes could enhance ASFV replication in PAMs. This showed that SwIFITM1a, -1b, -2, -3, and -5 can restrict ASFV replication individually, and all of them play a restrictive part in the early or late stage of ASFV replication. We blocked the constitutive expression of endogenous IFITMs in Vero cells using a CRISPR-Cas9 system and then infected them with ASFV. The results indicated that the knockout of endogenous IFITMs could enhance ASFV replication (9, 35). Finally, we analyzed the antiviral effect of SwIFITMs on ASFV infection in csIFITMs− Vero cells. The overexpression of SwIFITM1a, -1b, -2, -3, and -5 was found to potently restrict ASFV replication, which was consistent with the previous experimental results in wild-type Vero cells.

The GZ201801 strain of ASFV we used is a non-adapted field isolate which replication is not supported in Vero cells. However, our results may be contrary to this conclusion. In this study, we used the GZ201801 strain to infect Vero cells, the virus titres could reach more than 10^5 HAD50/mL at 36 hpi. Perhaps the

![FIGURE 4](Cai et al. Swine IFITMs Inhibit ASFV Replication)
virus has mutated during Vero cell passage and produced adaptability. In addition, it is also possible that the Vero cells we used are different from those used in other laboratories, resulting in mutations in the culture process, which can make the strain adapt to growth. African green monkey cells MA-104 has been showed to be suitable for ASFV field isolate (36). Similarly, it may not be uncommon for the GZ201801 strain to adapt in Vero cells which are also African green monkey cells.

SwIFITM proteins play different antiviral roles due to their different distribution and expression in cells. Given that ASFV entry is strongly dependent on endocytosis, SwIFITM1a and -1b may restrict the fusion of ASFV membrane and plasma membrane, and then inhibit viral entry (37). SwIFITM2 and -3 may restrict ASFV entry and uncoating, and inhibit the release of virus in late endosomes or lysosomes (38, 39). Since little is known about the antiviral mechanism of IFITM5, SwIFITM5

**FIGURE 5 |** Generation and validation of csIFITM knockout Vero cell lines. (A) Three different sgRNA targeting sites and the result of sanger sequencing with WT and csIFITMs− Vero cells. (B) Expression of endogenous csIFITMs was detected by western blotting with β-actin used as a control. (C) Proliferation of csIFITMs−, control, and untreated Vero cells were detected by the CCK-8 Cell Counting method. The csIFITMs−, control, and untreated Vero cells were infected with 0.1 MOI of ASFV; (D, E) the virus replication levels of ASFV were determined by western blotting at 36 hpi, and band densitometry for each protein was determined, and the density quantitative ratios of each viral or SwIFITM protein and β-actin were calculated, ratio of SwIFITM protein and β-actin served as a control; (F) the expression levels of p72 protein were detected by RT-qPCR with β-actin used as a control at 36 hpi; (G) the viral titration of progeny virus was tested in HAD assay. Samples were analyzed in triplicate, and three independent experiments were performed. **p < 0.01; ***p<0.001 vs empty vector control group. Error bars indicate standard deviation.
may play its antiviral role by interacting with other homologues, but further research is still needed to verify it.

This study verifies that SwIFITMs are a group of antiviral restriction factors, which means it may be possible to develop them as antiviral drugs or vaccine targets. Although there is still a need to determine the antiviral functions and molecular mechanisms of SwIFITMs against ASFV, our research will further expand our understanding of the anti-ASFV activity of porcine IFITM.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the South China Agricultural University Experimental Animal Welfare Ethics Committee.

AUTHOR CONTRIBUTIONS

Conceptualization: GZ and GL. Methodology: SC, ZZ, and JC. Software: SC, ZZ, JC, and LZ. Validation: RS, FZ, ZL, and JO. Formal Analysis: SC and ZZ. Investigation: SC and LX. Resources: SC and GL. Writing – Original Draft Preparation: SC. Writing – Review & Editing: GZ and GL. Visualization: SC. Supervision: PZ and GZ. Project Administration: PZ and GZ. Funding Acquisition: GZ. All authors contributed to the article and approved the submitted version.

FUNDING

This research was funded by the Key-Area Research and Development Program of Guangdong Province [grant number 2019B020211003], National Natural Science Foundation of China [grant number 31941004], The National Key Research and Development Program of China (2021YFD1800104), Independent Research and Development Projects of Maoming Laboratory (2021ZZ003) and China Agriculture Research System of MOF and MARA (cars-35).
REFERENCES

1. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus. Cell (2009) 139(7):1243–54. doi: 10.1016/j.cell.2009.12.017

2. Li LF, Yu J, Zhang Y, Yang Q, Li Y, Zhang L, et al. Interferon-Inducible Oligosaccharide Synthetase-Like Protein Acts as an Antiviral Effector Against Classical Swine Fever Virus via the MD-2–Mediated Type I Interferon-Signaling Pathway. J Virol (2017) 91(11):5114–6. doi: 10.1128/JVI.01514-16

3. Chan YK, Huang IC, Farzan M. IFITM Proteins Restrict Antibody-Dependent Enhancement of Dengue Virus Infection. PLoS One (2012) 7(3): e34508. doi: 10.1371/journal.pone.0034508

4. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melchyan GB. IFITM3 Restricts Influenza A Virus Entry by Blocking the Formation of Fusion Pores Following Virus-Endosome Hemifusion. PLoS Pathog (2014) 10(4):e1004048. doi: 10.1371/journal.ppat.1004048

5. Narayana SK, Helbig KJ, McCormick EM, Eyre NS, Bull RA, Eltahla A, et al. The IFITM3 Protein Inhibits Dengue Virus Infection. Proc Natl Acad Sci U S A (2015) 112(11):E1273–8. doi: 10.1073/pnas.1425317112

6. Wrensch F, Karsten GB, Gnirss K, Hoffmann M, Lu K, Takada A, et al. Chicken Interferon-Inducible Transmembrane Protein Mediated Inhibition of Host Cell Entry of Ebola Viruses. Infect Dis (2015) 21(Suppl 2):S210–8. doi: 10.1093/infd/jivt055

7. Zhu R, Wang J, Lei XY, Gui JF, Zhang QY. Evidence for Paralichthys Olivaceus Classical Swine Fever Virus Oligoadenylate Synthetase-Like Protein Acts as an Antiviral Effector Against Classical Swine Fever Virus: An Emerging DNA Arbovirus. Front Immunol (2018) 9:225. doi: 10.3389/fimmu.2018.00228

8. Smith SE, Gibson MS, Wash RS, Ferrara F, Wright E, Temperton N, et al. Influence of Interferon-Inducible Transmembrane Protein 3 Restricts Influenza Viruses and Lyssaviruses In Vitro. J Virol (2013) 87(23):12957–66. doi: 10.1128/JVI.01443-13

9. Muñoz-Moreno R, Cuesta-Geijo MA, Martínez-Romero C, Barrado-Gil L, Galindo I, Garcia-Sastre A, et al. Antiviral Role of IFITM Proteins in African Swine Fever Virus Infection. PLoS One (2016) 11(4):e0154366. doi: 10.1371/journal.pone.0154366

10. Ivanovic T, Choi JL, Whelan SP, van Oijen AM, Harrison SC. Influenza-Virus Membrane Fusion by Cooperative Fold-Back of Stochastically Induced Hemagglutinin Intermediates. elife (2013) 2:e00333. doi: 10.7554/eLife.00333

11. Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, et al. Chicken Interferon-Inducible Transmembrane Protein 3 Restricts Influenza Viruses and Lyssaviruses In Vitro. J Virol (2013) 87(23):12957–66. doi: 10.1128/JVI.01443-13

12. Liu Y, Goraya MU, Yuan X, Zhang B, Chiu SH, Chen JL. Functional Involvement of Interferon-Inducible Transmembrane Proteins in Antiviral Immunity. Front Microbiol (2019) 10:1097. doi: 10.3389/fmicb.2019.01097

13. Lanz C, Yanguez E, Andenmatten D, Stertz S. Swine Interferon-Inducible Transmembrane Proteins Potently Inhibit Influenza A Virus Replication. J Virol (2015) 89(1):863–9. doi: 10.1128/JVI.02516-14

14. Diamond MS, Farzan M. The Broad-Spectrum Antiviral Functions of IFIT and IFITM Proteins. Nat Rev Immunol (2013) 13(1):46–57. doi: 10.1038/nri3344

15. Huang IC, Bailey CC, Weyer JL, Radosztsky SR, Becker MM, Chiang J, et al. Distinct Patterns of IFITM-Mediated Restricted Fibrovirus, SARS Coronavirus, and Influenza A Virus. PLoS Pathog (2011) 7(1):e1001258. doi: 10.1371/journal.ppat.1001258

16. John SP, Chin CR, Ferreira JM, Feeley EM, Aker AM, Savidis G, et al. The CD225 Domain of IFITM3 Is Required for Both IFITM Protein Association and Inhibition of Influenza A Virus and Dengue Virus Replication. J Virol (2013) 87(14):7837–52. doi: 10.1128/JVI.00481-13

17. Lu J, Pan Q, Rong LW, He W, Liu SL, Liang C. The IFITM Proteins Inhibit HIV-1 Infection. J Virol (2011) 85(5):2126–37. doi: 10.1128/JVI.01531-10

18. Alonso C, Borca M, Dixon L, Revilla Y, Rodriguez F, Escribano JM. ICTV Virus Taxonomy Panel. Taxonomic Proposal: Asfarviridae. J Gen Virol (2018) 99:613–4. doi: 10.1099/jgv.0.001809

19. Dixon LK, Sun H, Roberts H. African Swine Fever. Antiviral Res (2019) 165:34–41. doi: 10.1016/j.antiviral.2019.02.018

20. Shalem O, Sanjana NE, Hartenian E, Xi S, Scott DA, Tarjei M, et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science (2014) 343(6166):84–7. doi: 10.1126/science.1247005
